Industries > Pharma > Global Precision Medicine Market Forecast 2019-2029

Global Precision Medicine Market Forecast 2019-2029

Companion Diagnostics, Biomarker-based Test, Targeted Therapeutics, Pharmacogenomics, Molecular Diagnostics, Pharmaceuticals & Biotechnology Companies, Diagnostic Companies, Healthcare IT/Big Data Companies, Clinical Laboratories, Cancer, Cardiovascular Diseases, Central Nervous System, Infectious Diseases

PUBLISHED: 30 May 2019
PAGES: 212
PRODUCT CODE: PHA0424

Clear
WOOCS 2.2.1

The global precision medicine market is expected to grow at an estimated CAGR of 10.5% from 2018 to 2029. In the precision medicine market, the Diagnostic Tool companies’ segment is dominating the global market and accounted for $23.36 billion in 2018 due to the development of large number of diagnostic and genetic tests.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 212-page report you will receive 98 tables and 63 figures– all unavailable elsewhere.

The 212-page report provides clear detailed insight into the global precision medicine market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Precision Medicine Market forecasts from 2019-2029

• Along with revenue prediction for the overall market for the global precision medicine market, our investigation shows forecasts to 2029 for the market segmented by technology:
– Companion Diagnostics
– Biomarker-based Test
– Targeted Therapeutics
– Pharmacogenomics
– Molecular Diagnostics

The report discusses key trends, developments and participants.

• This report breaks down the precision medicine market forecast to 2029 by end-users:
– Pharmaceuticals & Biotechnology Companies
– Diagnostic Companies
– Healthcare IT/Big Data Companies
– Clinical Laboratories

The report discusses key trends, developments and participants.

• This report also breaks down the precision medicine market forecast to 2029 by therapeutic application:
– Cancer
– Cardiovascular Diseases
– Central Nervous System
– Infectious Diseases
– Immunology
– Others

The report discusses key trends, developments and participants.

• This study provides precision medicine market forecasts to 2029 for these regional markets:
– North America: US & Canada
– Europe: Germany, UK, France, Italy, Spain, Rest of Europe
– Asia-Pacific: China, japan, India, Australia, South Korea, Rest of Asia-Pacific
– Middle East & Africa: South Africa, Saudi Arabia, Rest of Middle East & Africa
– Latin America: Brazil, Mexico, Rest of Latin America

For each regional market, the report discusses key trends, developments and participants.

• This report profiles selected leading companies that are the main players in the global precision medicine market:
– Abbott
– Danaher Corporation
– GE Healthcare
– GlaxoSmithKline
– Illumina, Inc.
– Johnson & Johnson
– Laboratory Corporation of America Holdings
– Novartis
– Pfizer
– QIAGEN
– Thermo Fisher Scientific, Inc.

Global Precision Medicine Market Forecast 2019-2029

• Our study discusses the drivers, restraints as well as the opportunities in the global precision medicine market.

• This study also analyzed the global precision medicine market with Porter’s Five Forces Analysis as well as Value Chain Analysis

• This report discusses selected market developments in the precision medicine market: partnership, collaboration, join venture, acquisitions, product launch, product development, expansions, patents, approvals.

Visiongain’s study is intended for anyone requiring commercial analyses for the global precision medicine market. You find data, trends and predictions.

Buy our report today Global Precision Medicine Market Forecast 2019-2029: Companion Diagnostics, Biomarker-based Test, Targeted Therapeutics, Pharmacogenomics, Molecular Diagnostics, Pharmaceuticals & Biotechnology Companies, Diagnostic Companies, Healthcare IT/Big Data Companies, Clinical Laboratories, Cancer, Cardiovascular Diseases, Central Nervous System, Infectious Diseases.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Global Precision Medicine Market Forecast 2019-2029


Download sample pages

Complete the form below to download your free sample pages for Global Precision Medicine Market Forecast 2019-2029


Latest Pharma news

Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031

We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

29 July 2021

READ

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

READ

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

READ

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

READ

Categories